Using Telehealth for Diagnosis and Management of Non‐Alcoholic Fatty Liver Disease
Hamid‐Reza Moein, Elvis J Arteaga, Souvik Sarkar – 28 April 2022
Using Telehealth for Diagnosis and Management of Non‐Alcoholic Fatty Liver Disease
Hamid‐Reza Moein, Elvis J Arteaga, Souvik Sarkar – 28 April 2022
A new tool to predict future liver allograft dysfunction?
Jonathan Rice, JP Norvell – 28 April 2022
A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis
Akiko Eguchi, Motoh Iwasa, Minori Yamada, Yasuyuki Tamai, Ryuta Shigefuku, Hiroshi Hasegawa, Yoshifumi Hirokawa, Akinobu Hayashi, Koji Okuno, Yuki Matsushita, Takuma Nakatsuka, Kenichiro Enooku, Koji Sakaguchi, Yoshinao Kobayashi, Tetsuji Yamaguchi, Masatoshi Watanabe, Yoshiyuki Takei, Hayato Nakagawa – 28 April 2022 – Caspase‐generated fragmented cytokeratin 18 (fCK18) is recognized as a useful noninvasive biomarker in the diagnosis of nonalcoholic fatty liver disease (NAFLD), particularly nonalcoholic steatohepatitis (NASH).
Community‐based and HIV integrated testing for hepatitis B and C among key populations in Vietnam
Bao Ngoc Vu, Kim Do Tuan, An Khanh Tran, Long Khanh Tran, Kimberly Green, Khoa Trong Nguyen, Phuong Duc Cao – 28 April 2022
Using Telehealth for Diagnosis and Management of Non‐Alcoholic Fatty Liver Disease
Hamid‐Reza Moein, Elvis J Arteaga, Souvik Sarkar – 28 April 2022
Practical Approach to Starting a Telemedicine Program: Lessons From the Real World
Chanda Ho, Marina Serper – 28 April 2022
Telemedicine for Liver Transplant Evaluations: The Benefits and Risks
Hersh Shroff, Laura Kulik – 28 April 2022
Optimizing Hepatology Education in the Virtual World
Brian Kim, Norah A. Terrault – 28 April 2022
Practical Approach to Starting a Telemedicine Program: Lessons From the Real World
Chanda Ho, Marina Serper – 28 April 2022